Calidi Biotherapeutics Reports 2024 Financial Results and Progress

The latest update is out from Calidi Biotherapeutics ( (CLDI) ).

Calidi Biotherapeutics reported its fourth quarter and full-year 2024 financial results, highlighting significant advancements in its clinical programs. The company demonstrated the ability of its CLD-400 platform to deliver gene therapy to tumors and filed an IND for a Phase 1 trial of CLD-201 for solid tumors in March 2025. Recruitment began for a Phase 1 trial of CLD-101 in high-grade glioma patients at Northwestern University, and 14 patients were enrolled in a City of Hope trial for recurrent high-grade glioma. Financially, Calidi reduced its net loss and expenses in 2024 compared to 2023, with increased cash reserves by year-end.

More about Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company based in San Diego, California. The company specializes in developing proprietary stem cell-based platforms designed to enhance the immune system’s ability to fight cancer. These platforms utilize allogeneic stem cells to deliver oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors. Calidi’s technology aims to protect, amplify, and potentiate oncolytic viruses, improving efficacy and patient safety, with a focus on targeting disseminated solid tumors and potentially preventing metastatic disease.

YTD Price Performance: -44.92%

Average Trading Volume: 1,444,122

Technical Sentiment Signal: Buy

Current Market Cap: $16.95M

Learn more about CLDI stock on TipRanks’ Stock Analysis page.